ATE468863T1 - Gentherapie für zerebrale gefässerkrankungen - Google Patents

Gentherapie für zerebrale gefässerkrankungen

Info

Publication number
ATE468863T1
ATE468863T1 AT00961050T AT00961050T ATE468863T1 AT E468863 T1 ATE468863 T1 AT E468863T1 AT 00961050 T AT00961050 T AT 00961050T AT 00961050 T AT00961050 T AT 00961050T AT E468863 T1 ATE468863 T1 AT E468863T1
Authority
AT
Austria
Prior art keywords
cerebral
gene therapy
vascular diseases
cerebrovascular
cerebral vascular
Prior art date
Application number
AT00961050T
Other languages
English (en)
Inventor
Ryuichi Morishita
Toshio Ogihara
Original Assignee
Anges Mg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges Mg Inc filed Critical Anges Mg Inc
Application granted granted Critical
Publication of ATE468863T1 publication Critical patent/ATE468863T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT00961050T 1999-09-21 2000-09-18 Gentherapie für zerebrale gefässerkrankungen ATE468863T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP26702499 1999-09-21
JP2000241205 2000-08-09
PCT/JP2000/006347 WO2001021214A1 (en) 1999-09-21 2000-09-18 Gene therapy for cerebrovascular disorders

Publications (1)

Publication Number Publication Date
ATE468863T1 true ATE468863T1 (de) 2010-06-15

Family

ID=26547690

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00961050T ATE468863T1 (de) 1999-09-21 2000-09-18 Gentherapie für zerebrale gefässerkrankungen

Country Status (12)

Country Link
US (1) US6936594B1 (de)
EP (1) EP1132098B1 (de)
JP (1) JP4642303B2 (de)
KR (1) KR100768023B1 (de)
CN (1) CN1194762C (de)
AT (1) ATE468863T1 (de)
AU (1) AU774990B2 (de)
CA (1) CA2348906A1 (de)
DE (1) DE60044453D1 (de)
HK (1) HK1042645A1 (de)
TW (1) TWI250875B (de)
WO (1) WO2001021214A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2230819C (en) * 1995-08-29 2009-04-14 Sumitomo Pharmaceuticals Co., Ltd. Medicament comprising hgf gene
KR20010093804A (ko) 1999-10-08 2001-10-29 무라야마 마사노리 심근증 유전자 치료
US20020164310A1 (en) 2001-03-02 2002-11-07 Mgvs Ltd. Nucleic acid constructs, cells transformed therewith and methods utilizing same for inducing liver regeneration and alleviation of portal hypertension
US7981863B2 (en) 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
AU2002349583B2 (en) * 2001-11-28 2007-11-22 Anges Mg, Inc. Genetic remedies for neurodegenerative diseases
JP2003238439A (ja) * 2002-02-13 2003-08-27 Yasuhiko Tabata 虚血治療剤
EP1532987A4 (de) * 2002-06-06 2005-12-28 Anges Mg Inc Mittel für die gentherapie bei zerebrovaskulären erkrankungen
US20080213348A1 (en) * 2002-06-06 2008-09-04 Anges Mg, Inc. Agents for gene therapy of cerebrovascular disorders
CA2541603A1 (en) * 2003-10-14 2005-04-21 Kringle Pharma Inc. Agent for improving mental disorders
JP4775940B2 (ja) * 2004-06-29 2011-09-21 アンジェスＭｇ株式会社 アロディニアの治療、改善、予防剤
US20090082263A1 (en) * 2004-07-29 2009-03-26 Anges, Mg, Inc. Drug and method for improving brain function
US20080025962A1 (en) * 2004-11-30 2008-01-31 Angesmg,Inc. Remedy for Alzheimer's Disease
EP1863519B1 (de) * 2005-03-31 2013-09-25 The General Hospital Corporation Modulation von hgf/hgfr-aktivität zur behandlung von lymphödem
US7977314B2 (en) 2005-12-02 2011-07-12 Amorfix Life Sciences Limited Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
WO2016069760A1 (en) * 2014-10-31 2016-05-06 Steven Yu Method of treating dementia by intranasal administration of vegf gene therapy
WO2017210343A1 (en) * 2016-06-01 2017-12-07 The University Of Virginia Patent Foundation Methods and compositions for modulating lymphatic vessels in the central nervous system

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686085A (en) 1980-04-14 1987-08-11 Thomas Jefferson University Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders
JPH0741429A (ja) * 1993-07-30 1995-02-10 Mitsubishi Chem Corp 神経障害改善薬
JP3680114B2 (ja) 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
JPH08231416A (ja) * 1995-02-24 1996-09-10 Mitsubishi Chem Corp 血栓症治療剤
EA001616B1 (ru) * 1995-02-28 2001-06-25 Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре
CA2230819C (en) * 1995-08-29 2009-04-14 Sumitomo Pharmaceuticals Co., Ltd. Medicament comprising hgf gene
US5732654A (en) * 1995-10-20 1998-03-31 The First Republic Corporation Of America Open air mariculture system and method of culturing marine animals
US6121246A (en) 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
WO1997030155A1 (en) * 1996-02-15 1997-08-21 Chiron Corporation Gene therapy method using fgf-5
CA2307953A1 (en) 1997-10-27 1999-05-06 Merck & Co., Inc. Gene therapy for stimulation of angiogenesis
WO1999036103A1 (en) * 1998-01-16 1999-07-22 Mcgill University Prevention and treatment of neuropathy by hepatocyte growth factor
JPH11246434A (ja) * 1998-02-25 1999-09-14 Sumitomo Pharmaceut Co Ltd ｂａｘの低下及び／又はｂｃｌ−２の増加誘導剤
US6199554B1 (en) * 1998-03-27 2001-03-13 The Brigham And Women's Hospital, Inc. Method and apparatus for combining injury-mediated therapy and drug delivery

Also Published As

Publication number Publication date
EP1132098A4 (de) 2002-07-31
KR20010089469A (ko) 2001-10-06
US6936594B1 (en) 2005-08-30
CN1322143A (zh) 2001-11-14
EP1132098B1 (de) 2010-05-26
TWI250875B (en) 2006-03-11
AU7314800A (en) 2001-04-24
JP4642303B2 (ja) 2011-03-02
DE60044453D1 (de) 2010-07-08
CN1194762C (zh) 2005-03-30
EP1132098A1 (de) 2001-09-12
AU774990B2 (en) 2004-07-15
KR100768023B1 (ko) 2007-10-17
HK1042645A1 (en) 2002-08-23
CA2348906A1 (en) 2001-03-29
WO2001021214A1 (en) 2001-03-29

Similar Documents

Publication Publication Date Title
ATE468863T1 (de) Gentherapie für zerebrale gefässerkrankungen
GR3036686T3 (en) Therapeutic uses of bactericidal/permeability increasing protein products
ATE466883T1 (de) Katalytische monoklonale antikörper mit proteaseaktivität zur selektiven lysis der proteinkomponente von mit pathologischen konditionen zusammenhängenden plaques und aggregaten
BR9506819A (pt) Derivados de ácido micofenólico substituídos na posiçao 5
IS6170A (is) Efni til öftrunar og meðferðar mýlildis
ATE194593T1 (de) 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten
NO931889D0 (no) Protease og beslektede dna-forbindelser
DE60039450D1 (de) Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung
DK1218509T3 (da) Fibroblast vækstfaktorlignende polypeptider
AU2378402A (en) Imaging, diagnosis and treatment of disease
DE69523654D1 (de) Verwendung von Ascorbyl-gamma-Linolenat und von Ascorbyl-dihomo-gamma-linolenat zur Behandlung von Asthma, Krebs, kardiovaskulären und inflammatorischen Erkrankungen
DK1220852T3 (da) Substituerede diazepaner
DE60108076D1 (de) Protein c derivate
WO2003038130A3 (en) Therapeutics and diagnostics for disorders of erythropoiesis
ATE348161T1 (de) Fctrx genannte proteine und dafür kodierende nuklein säure
ATE143809T1 (de) Placentaextrakt und verfahren zu seiner herstellung
ES2070934T3 (es) Derivados de oxotremorina 3- o 4-sustituidos.
WO2001036462A3 (en) Protein c derivatives
WO2001056593A3 (en) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
ATE401337T1 (de) Antiangiogene polypeptide
ATE364687T1 (de) Mutanten von milchsäurebakterien die mindestens eine peptidase überexprimeren
DE58906618D1 (de) Strobilurinderivate, ihre Herstellung und Verwendung.
DK0657431T3 (da) 4-Phenyl-3-substituerede 1,4-dihydropyridinestere med cerebral virkning.
MXPA03010739A (es) Moleculas de marcador endotelial tumoral 7-alfa y uso de las mismas.
ES1042459U (es) Futbolin.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties